153 related articles for article (PubMed ID: 22493355)
41. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
[TBL] [Abstract][Full Text] [Related]
42. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.
Vergani E; Frigerio S; Dugo M; Devecchi A; Feltrin E; De Cecco L; Vallacchi V; Cossa M; Di Guardo L; Manoukian S; Peissel B; Ferrari A; Gallino G; Maurichi A; Rivoltini L; Sensi M; Rodolfo M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573422
[TBL] [Abstract][Full Text] [Related]
43. Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins.
Zanna P; Maida I; Grieco C; Guida S; Turpin Sevilla MC; De Summa S; Tommasi S; Vena GA; Filotico R; Guida G
J Biol Regul Homeost Agents; 2013; 27(1):131-41. PubMed ID: 23489693
[TBL] [Abstract][Full Text] [Related]
44. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
45. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.
Bhaskaran S; Dileep KV; Deepa SS; Sadasivan C; Klausner M; Krishnegowda NK; Tekmal RR; VandeBerg JL; Nair HB
Mol Cancer Ther; 2013 Apr; 12(4):361-72. PubMed ID: 23543365
[TBL] [Abstract][Full Text] [Related]
46. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
47. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
48. BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
Willmore-Payne C; Holden JA; Hirschowitz S; Layfield LJ
Hum Pathol; 2006 May; 37(5):520-7. PubMed ID: 16647948
[TBL] [Abstract][Full Text] [Related]
49. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.
Soto JL; Cabrera CM; Serrano S; López-Nevot MA
BMC Cancer; 2005 Apr; 5():36. PubMed ID: 15819981
[TBL] [Abstract][Full Text] [Related]
50. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
[TBL] [Abstract][Full Text] [Related]
51. Germline MC1R variants and BRAF mutant melanoma.
Hacker E; Hayward NK
J Invest Dermatol; 2008 Oct; 128(10):2354-6. PubMed ID: 18787543
[TBL] [Abstract][Full Text] [Related]
52. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
53. MicroRNAs in the pathogenesis of malignant melanoma.
Glud M; Gniadecki R
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):142-50. PubMed ID: 22621697
[TBL] [Abstract][Full Text] [Related]
54. Lack of somatic alterations of MC1R in primary melanoma.
Kim RD; Curtin JA; Bastian BC
Pigment Cell Melanoma Res; 2008 Oct; 21(5):579-82. PubMed ID: 18761657
[TBL] [Abstract][Full Text] [Related]
55. Genetic variations of patients with familial or multiple melanoma in Southern Brazil.
Grazziotin TC; Rey MC; Bica CG; Pinto LA; Bonamigo RR; Puig-Butille JA; Cuellar F; Puig S
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e179-85. PubMed ID: 22621339
[TBL] [Abstract][Full Text] [Related]
56. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC
J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702
[TBL] [Abstract][Full Text] [Related]
57. MC1R variants increase risk of melanomas harboring BRAF mutations.
Fargnoli MC; Pike K; Pfeiffer RM; Tsang S; Rozenblum E; Munroe DJ; Golubeva Y; Calista D; Seidenari S; Massi D; Carli P; Bauer J; Elder DE; Bastian BC; Peris K; Landi MT
J Invest Dermatol; 2008 Oct; 128(10):2485-90. PubMed ID: 18368129
[TBL] [Abstract][Full Text] [Related]
58. Melanoma: What do all the mutations mean?
Davis EJ; Johnson DB; Sosman JA; Chandra S
Cancer; 2018 Sep; 124(17):3490-3499. PubMed ID: 29663336
[TBL] [Abstract][Full Text] [Related]
59. [Genotypic hypervariability of melanoma: a therapeutic challenge].
Dalle S; Martin-Denavit T; Thomas L
Med Sci (Paris); 2006 Feb; 22(2):178-82. PubMed ID: 16457759
[TBL] [Abstract][Full Text] [Related]
60. Assessment of BRAF and KIT mutations in Japanese melanoma patients.
Ashida A; Uhara H; Kiniwa Y; Oguchi M; Murata H; Goto Y; Uchiyama A; Ogawa E; Hayashi K; Koga H; Okuyama R
J Dermatol Sci; 2012 Jun; 66(3):240-2. PubMed ID: 22534474
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
